BioWorld MedTech

Nov. 13, 2015

Pixium Vision to challenge Second Sight with retinal implant

PARIS — The window is closing for first-to-market mover Second Sight (Sylmar, Calif.) as French start-up Pixium Vision (Paris) prepares a first-in-man trial for its retinal implant Iris-II. Read More

Inside the Beltway: Rates of deficiency letters, pendency up for 2015 PMAs

Medtronic's tiny, no-lead pacemaker on track for FDA approval in 2016

Derma dumps DFU trial for futility, exits drug development

Digisight goes mobile with ophthalmology technology

Agreements/Contracts: Protagen, Mikrogen agree to co-develop Lyme disease markers

World in review: Alivecor, C. Illies & Co. in East Asia distribution agreement

Financings: Optovue snags $30 million investment to drive innovation in OCT eye market

Product briefs

Briefly noted

People in places

MDD's Diagnostics Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 9, 2026.

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Development and characterization of anti-CD19 in vivo CAR T therapy

BioWorld Science

Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...

Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome

BioWorld Science

The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...